Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Incyte Corp.

Start price
Target price
Perf. (%)
€67.64
-
-4.58%

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Dependend from some customers or products
Incyte Corp.

Start price
Target price
Perf. (%)
€67.64
-
-4.58%

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Dependend from some customers or products
Incyte Corp.

Start price
Target price
Perf. (%)
€67.64
-
-4.58%

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Dependend from some customers or products
Teleflex Inc.

Start price
Target price
Perf. (%)
€320.00
-
1.88%

Revenue decline/stagnation expected
EBIT decline/stagnation expected
Low dividend yield expected
buy
Inovio Pharma

Start price
Target price
Perf. (%)
€11.30
€13.00
-16.37%

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Higher EBIT margin than peer group
EBIT decline/stagnation expected
Novan Inc

Start price
Target price
Perf. (%)
€1.68
€3.00
-21.43%

Could be very worthwhile Investment >20% year
buy
Merck KGaA

Start price
Target price
Perf. (%)
€141.75
€150.00
-4.41%

buy
Perrigo Co. plc

Start price
Target price
Perf. (%)
€37.00
-
-9.19%

Could be worthwhile Investment >10% per year
Undervalued
Higher risks for its business
buy
Viatris Inc.

Start price
Target price
Perf. (%)
€15.40
€19.00
-18.83%

Undervalued
High dividend yield expected
buy
Viatris Inc.

Start price
Target price
Perf. (%)
€15.40
€19.00
-18.83%

Undervalued
High dividend yield expected
buy
Viatris Inc.

Start price
Target price
Perf. (%)
€15.40
€19.00
-18.83%

Undervalued
High dividend yield expected
buy
GlaxoSmithKline plc

Start price
Target price
Perf. (%)
€14.65
€17.30
-2.85%

Could be very worthwhile Investment >20% year
High dividend yield expected
Good rating
Small Risks for its business
buy
GlaxoSmithKline plc

Start price
Target price
Perf. (%)
€14.65
€17.30
-2.85%

Could be very worthwhile Investment >20% year
High dividend yield expected
Good rating
Small Risks for its business
buy
Dexcom Inc.

Start price
Target price
Perf. (%)
€328.95
€350.00
-1.05%

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Sustainability is important
Higher risks for its business
buy
Heat Biologics Inc.

Start price
Target price
Perf. (%)
€11.10
-
-41.44%

Could be worthwhile Investment >10% per year
Capable Management
Good culture
Some uniques
buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€34.83
€37.00
0.11%

Could be worthwhile Investment >10% per year
Fair valuation
High dividend yield expected
Small challenges to pay loans and raise capital
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€36.00
-
-24.63%

Probably not worthwhile Investment
High risks for its business
Few uniques
Idexx Laboratories Inc.

Start price
Target price
Perf. (%)
€416.00
-
2.40%

EBIT growth >5% per year expected
Very low/no dividend yield expected
Idexx Laboratories Inc.

Start price
Target price
Perf. (%)
€416.00
-
2.40%

EBIT growth >5% per year expected
Very low/no dividend yield expected
Idexx Laboratories Inc.

Start price
Target price
Perf. (%)
€416.00
-
2.40%

EBIT growth >5% per year expected
Very low/no dividend yield expected
buy
Bayer AG

Start price
Target price
Perf. (%)
€56.11
€90.00
-8.70%

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
buy
Bayer AG

Start price
Target price
Perf. (%)
€56.11
€90.00
-8.70%

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€138.90
-
-4.06%

Future proof or reliable business model
Could be worthwhile Investment >10% per year
Fair valuation
Innovative
buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€138.90
-
-4.06%

Future proof or reliable business model
Could be worthwhile Investment >10% per year
Fair valuation
Innovative
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€82.00
€90.00
-13.41%

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Some uniques
Innovative